Epigenetic mediated transcriptional activation of PARP-1 participates in silica-associated malignant transformation of human bronchial epithelial cells

Toxicology Letters
Ai GaoLin Tian

Abstract

Silica was listed as a human carcinogen by International Agency for Research on Cancer (IARC) in 1996. However, the molecular mechanisms to induce cancer are not understood yet. Our recent published study showed that silica inhibited the expression of poly(ADP-ribose) polymerases-1 (PARP-1) mRNA. However, the mechanisms responsible for low PARP-1 expression have not yet been elucidated. In this study, the human bronchial epithelial cells (16HBE) were treated with 300 microg/ml silicon dioxide for 35 passages, the mode of silica-associated malignant transformation of human bronchial epithelial cells (M-16HBE) was established and identified by soft agar assay and nude mouse tumorigenesis. The mRNA expression and methylation status of PARP-1 in M-16HBE with or without treatment of the cytosine methylation inhibitor 5-aza-2'-deoxycytidine (5-aza) were detected by real-time PCR and methylation-specific PCR (MSP), respectively. The data showed that silica decreased PARP-1 expression at the transcriptional levels in M-16HBE and the above epigenetic inhibitors reversed the transcriptional inhibition of PARP-1 through the demethylation of PARP-1, suggesting that the epigenetic mediated transcriptional activation of PARP-1.

References

Jan 1, 1994·American Journal of Respiratory Cell and Molecular Biology·A L CozensD C Gruenert
Sep 6, 2001·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·A Bürkle
Jan 29, 2002·International Immunopharmacology·Min DingVal Vallyathan
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·A GiuliettiC Mathieu
Jun 18, 2003·Cell·W Lee Kraus, John T Lis
Jun 30, 2006·Toxicology and Applied Pharmacology·Tiffany G BredfeldtA Jay Gandolfi
Jun 24, 2008·Toxicological Sciences : an Official Journal of the Society of Toxicology·Lanlan ZhouQiaoyuan Yang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.